Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PEOPLE - Bioheart (US) makes appointments:

This article was originally published in Clinica

Executive Summary

Bioheart (Weston, Florida), a discoverer, developer and commercialiser of cellular-based products, has strengthened its management team with several new appointments, three of whom, Manny Villafana, Richard Spencer and Norman Dann, have been appointed to the board. Mr Villafana is a former executive of Medtronic and founder of Cardiac Pacemakers (now part of Guidant CRM), St Jude Medical and ATS Medical. Mr Spencer, is the former president of the marketing division of Cordis (now Cordis Johnson & Johnson) and vice-president of Cordis Dow, will also serve as a consultant to Bioheart. Mr Dann, who has over 40 years of industry experience, is a former board member, director and consultant for World Medical Manufacturing Corporation (now Medtronic AVE World Medical).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT066058

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel